Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin E receptor 4 (EP4) is a G protein-coupled receptor that binds prostaglandin E2 (PGE2). Upon activation, it primarily couples to Gs proteins, leading to increased intracellular cAMP levels. EP4 is widely expressed on immune cells and plays a role in various physiological and pathological processes, including smooth muscle relaxation, immune modulation, and cancer progression. It is a significant target for anti-inflammatory and immuno-oncology therapies.
Agonism of EP4 receptor increases cAMP and activates protein kinase A (PKA), which in turn activates transcription factors such as CREB. Antagonism of EP4 can restore anti-tumor immunity by reactivating NK cell functions and restoring recruitment/functionality of cross-presenting DCs within tumors.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin E receptor 4 (EP4).